Symbiotix Biotherapies Overview
- Founded
-
2009
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
Symbiotix Biotherapies General Information
Description
Developer of a novel class of molecular therapeutics intended to treat inflammatory bowel disease. The company's novel class of molecular therapeutics are oral agents based on molecules derived from the human microbiom which are used for multiple sclerosis and other serious immune-mediated diseases, enabling patients to improve their lives and treat inflammatory disaeses.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- One International Place
- Suite 1400
- Boston, MA 02110
- United States
Symbiotix Biotherapies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Out of Business | 01-Oct-2019 | 000 | Completed | Out of Business | ||
| 5. Later Stage VC (Series A) | 01-Nov-2017 | 000 | 000 | 0000 | Completed | Generating Revenue |
| 4. Grant | 21-Sep-2016 | 000 | Completed | Startup | ||
| 3. Later Stage VC | Completed | Startup | ||||
| 2. Grant | 01-Jun-2015 | $2.98M | Completed | Startup | ||
| 1. Grant | 15-Jul-2014 | $720K | Completed | Startup |
Symbiotix Biotherapies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A3 | 00,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | |
| Series A2 | 000,000 | 00.000000 | 000.0 | 000.0 | 00 | 000.0 | 0.000 | |
| Series A1 | 303,796 | $0.001000 | $7.9 | $7.9 | 1x | $7.9 | 10.88% |